Molecular sampling of prostate cancer: a dilemma for predicting disease progression

BACKGROUND: Current prostate cancer prognostic models are based on pre-treatment prostate specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are inadequate to accurately predict disease progression. Hence, we sought to develop a molecular panel for prostate can...

Descripción completa

Detalles Bibliográficos
Autores principales: Sboner, Andrea, Demichelis, Francesca, Calza, Stefano, Pawitan, Yudi, Setlur, Sunita R, Hoshida, Yujin, Perner, Sven, Adami, Hans-Olov, Fall, Katja, Mucci, Lorelei A, Kantoff, Philip W, Stampfer, Meir, Andersson, Swen-Olof, Varenhorst, Eberhard, Johansson, Jan-Erik, Gerstein, Mark B, Golub, Todd R, Rubin, Mark A, Andrén, Ove
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855514/
https://www.ncbi.nlm.nih.gov/pubmed/20233430
http://dx.doi.org/10.1186/1755-8794-3-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855514/
https://www.ncbi.nlm.nih.gov/pubmed/20233430
http://dx.doi.org/10.1186/1755-8794-3-8

Ejemplares similares